Research Papers:

KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin

Shengjun Fan _, Xin Li, Lu Tie, Yan Pan and Xuejun Li

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:13520-13537. https://doi.org/10.18632/oncotarget.5876

Metrics: PDF 1530 views  |   HTML 2507 views  |   ?  


Shengjun Fan1, Xin Li1, Lu Tie1, Yan Pan1, Xuejun Li1

1State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University Health Science Center and Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, China

Correspondence to:

Xuejun Li, e-mail: [email protected]

Keywords: EPO, KIAA0101, renal cell carcinoma, proliferation and migration, proteomics

Received: August 02, 2015     Accepted: September 27, 2015     Published: November 12, 2015


Erythropoietin (EPO) is a frequently prescribed anti-anemic drug for patients with advanced renal carcinoma. However, recent evidence from clinical studies suggested that EPO accelerated tumor progression and jeopardized the 5-year survival. Herein, we show, starting from the in silico microarray bioinformatics analysis, that activation of Erythropoietin signaling pathway enhanced renal clear carcinoma (RCC) progression. EPO accelerated the proliferative and migratory ability in 786-O and Caki-2 cells. Moreover, comparative proteomics expression profiling suggested that exogenous EPO stimulated RCC progression via up-regulation of KIAA0101 expression. Loss of KIAA0101 impeded the undesirable propensity of EPO in RCC. Finally, low expression of KIAA0101 was associated with the excellent prognosis and prognosticated a higher 5-year survival in human patients with renal carcinoma. Overall, KIAA0101 appears to be a key promoter of RCC malignancy induced by EPO, which provide mechanistic insights into KIAA0101 functions, and pave the road to develop new therapeutics for treatment of cancer-related and chemotherapy-induced anemia in patients with RCC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5876